

Client Update

BioReference | genpath
LABORATORIES
OPKO Health Companies

April 2022 – COVID-19 CARES ACT – IMPORTANT NEW INFORMATION

Page 1 of 1

Dear Valued Clients,

The Uninsured Program supported by the CARES Act of 2020 has stopped accepting claims for COVID-19 testing and treatment due to a lack of sufficient funds. All claims submitted before March 22, 2022 will be paid subject to the availability of funds. Claims submitted by BioReference Laboratories after this date will not be adjudicated or paid.

Therefore, BioReference will no longer be submitting claims to the COVID-19 federal fund for payment. In light of this development, patients without active insurance will be responsible for payment of this claim at a discounted self-pay rate.

In order to avoid unexpected patient invoices, please provide current insurance information for all COVID-19 specimens from patients that are actively insured.

Any patient in need of assistance with a payment or in need of a payment plan may contact the BioReference Billing Department at 833-469-5227 for an available service representative.

Thank you for your cooperation and understanding.

Best Regards,
BioReference